CMS Entry id: 2710 | Channel: News landing page | Template: news/index


16 May 2017

Creator of CANTAB receives Gold Medal Award from The Society of Biological Psychiatry

Co-creator of CANTAB (Cambridge Neuropsychological Test Automated Battery) Professor Trevor Robbins is to receive the Gold Medal Award on May 19, 2017, at the 72nd Annual Meeting in San Diego, California. The award honours pioneering contributions in the field of biological psychiatry and significant and sustained work that extends knowledge in the field.

3 May 2017

Cambridge Cognition CSO named in Top 40 Healthcare Transformers

Company CSO honoured at this year's ceremony celebrating leading health-tech innovators.

16 March 2017

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab

Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.

8 March 2017

Design and rationale of the EBBINGHAUS trial

The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.

7 March 2017

Cambridge Cognition launches web-based testing for virtual research

Cambridge Cognition today announces the launch of a new web-based testing product for conducting academic and clinical research studies online.

6 March 2017

Poster presentation at the International Congress on Schizophrenia Research

Senior Scientist, Kiri Granger, PhD will be presenting a poster at the International Congress on Schizophrenia Research (ICOSR) from the 24th to 28th March.

Share this